Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
BOTA's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BOTA: No Debt )
BOTA' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: No Debt

Equity to Asset 0.80
BOTA's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BOTA: 0.80 )
BOTA' s 10-Year Equity to Asset Range
Min: 0.25   Max: 0.85
Current: 0.8

0.25
0.85
Interest Coverage No Debt
BOTA's Interest Coverage is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BOTA: No Debt )
BOTA' s 10-Year Interest Coverage Range
Min: 1   Max: 9999.99
Current: No Debt

1
9999.99
F-Score: 2
Z-Score: 2.31
M-Score: -0.76
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -10.78
BOTA's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BOTA: -10.78 )
BOTA' s 10-Year Operating margin (%) Range
Min: -171.38   Max: 49.83
Current: -10.78

-171.38
49.83
Net-margin (%) -10.20
BOTA's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BOTA: -10.20 )
BOTA' s 10-Year Net-margin (%) Range
Min: -178.54   Max: 44.58
Current: -10.2

-178.54
44.58
ROE (%) -7.40
BOTA's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BOTA: -7.40 )
BOTA' s 10-Year ROE (%) Range
Min: -79.37   Max: 55.92
Current: -7.4

-79.37
55.92
ROA (%) -5.89
BOTA's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BOTA: -5.89 )
BOTA' s 10-Year ROA (%) Range
Min: -39   Max: 33.73
Current: -5.89

-39
33.73
ROC (Joel Greenblatt) (%) -47.17
BOTA's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BOTA: -47.17 )
BOTA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -11621.43   Max: 93.37
Current: -47.17

-11621.43
93.37
Revenue Growth (%) -1.40
BOTA's Revenue Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BOTA: -1.40 )
BOTA' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 5
Current: -1.4

0
5
EBITDA Growth (%) -30.60
BOTA's EBITDA Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BOTA: -30.60 )
BOTA' s 10-Year EBITDA Growth (%) Range
Min: -77.1   Max: 114.1
Current: -30.6

-77.1
114.1
EPS Growth (%) -48.10
BOTA's EPS Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BOTA: -48.10 )
BOTA' s 10-Year EPS Growth (%) Range
Min: -48.1   Max: 5.7
Current: -48.1

-48.1
5.7
» BOTA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

BOTA Guru Trades in Q3 2013

Jim Simons 318,347 sh (+0.65%)
» More
Q4 2013

BOTA Guru Trades in Q4 2013

Jim Simons 314,805 sh (-1.11%)
» More
Q1 2014

BOTA Guru Trades in Q1 2014

George Soros 39,500 sh (New)
Jim Simons 320,905 sh (+1.94%)
» More
Q2 2014

BOTA Guru Trades in Q2 2014

Jim Simons 321,105 sh (+0.06%)
George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BOTA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 Sold Out $2.36 - $6.08 $ 2.19-42%0
George Soros 2014-03-31 New Buy$4.19 - $6.98 $ 2.19-61%39500
George Soros 2011-09-30 Sold Out 0.0014%$9.93 - $34.49 $ 2.19-85%0
Daniel Loeb 2011-06-30 Sold Out 0.92%$28.61 - $34.97 $ 2.19-93%0
George Soros 2011-06-30 New Buy$28.61 - $34.97 $ 2.19-93%18800
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.80
BOTA's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BOTA: 0.80 )
BOTA' s 10-Year P/B Range
Min: 0.8   Max: 10.25
Current: 0.8

0.8
10.25
P/S 0.96
BOTA's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BOTA: 0.96 )
BOTA' s 10-Year P/S Range
Min: 0.96   Max: 25.86
Current: 0.96

0.96
25.86
EV-to-EBIT 0.46
BOTA's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BOTA: 0.46 )
BOTA' s 10-Year EV-to-EBIT Range
Min: 14.7   Max: 548.4
Current: 0.46

14.7
548.4
Current Ratio 4.84
BOTA's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BOTA: 4.84 )
BOTA' s 10-Year Current Ratio Range
Min: 1.35   Max: 26.34
Current: 4.84

1.35
26.34
Quick Ratio 4.84
BOTA's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BOTA: 4.84 )
BOTA' s 10-Year Quick Ratio Range
Min: 0.76   Max: 26.34
Current: 4.84

0.76
26.34

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.38
BOTA's Price/Net Cash is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BOTA: 1.38 )
BOTA' s 10-Year Price/Net Cash Range
Min: 1.19   Max: 72.7
Current: 1.38

1.19
72.7
Price/Net Current Asset Value 0.92
BOTA's Price/Net Current Asset Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BOTA: 0.92 )
BOTA' s 10-Year Price/Net Current Asset Value Range
Min: 1.19   Max: 98.26
Current: 0.92

1.19
98.26
Price/Tangible Book 0.80
BOTA's Price/Tangible Book is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BOTA: 0.80 )
BOTA' s 10-Year Price/Tangible Book Range
Min: 1.02   Max: 30.32
Current: 0.8

1.02
30.32
Price/DCF (Projected) 1.56
BOTA's Price/DCF (Projected) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BOTA: 1.56 )
BOTA' s 10-Year Price/DCF (Projected) Range
Min: 2.28   Max: 45.14
Current: 1.56

2.28
45.14
Price/Median PS Value 0.19
BOTA's Price/Median PS Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BOTA: 0.19 )
BOTA' s 10-Year Price/Median PS Value Range
Min: 0.06   Max: 4.85
Current: 0.19

0.06
4.85
Earnings Yield (Greenblatt) 217.40
BOTA's Earnings Yield (Greenblatt) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BOTA: 217.40 )
BOTA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 6.8
Current: 217.4

0.2
6.8
Forward Rate of Return (Yacktman) 11.19
BOTA's Forward Rate of Return (Yacktman) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. BOTA: 11.19 )
BOTA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -12.7   Max: 9.5
Current: 11.19

-12.7
9.5

Business Description

Industry: »
Compare: » details
Traded in other countries:NB1N.Germany
Biota Pharmaceuticals Inc was incorporated in Delaware since 1969. It is a clinical stage, biopharmaceutical company, engaged in the discovery and development of novel products to treat serious and potentially life-threatening infectious diseases. The Company's products in development are NicVAX [Nicotine Conjugate Vaccine], a proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Its research and development facilities are located in Melbourne, Australia and Oxford, United Kingdom.
» More Articles for BOTA

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlights: VCRA, CLUB, ARGS, ONTX, BOTA Jun 08 2014 

More From Other Websites
Biota Pharmaceuticals to Host Conference Call to Report Fourth Quarter and Year-End 2014 Financial... Sep 15 2014
Biota to Present Preclinical Data on RSV Compound BTA-C585 at ICAAC Meeting Sep 04 2014
BIOTA PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 01 2014
Midday movers: Chevron, Clorox, Harley-Davidson & more Aug 01 2014
Biota's lead drug fails mid-stage study, shares slump Aug 01 2014
BIOTA ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Biota... Aug 01 2014
Biota's influenza drug fails in mid-stage study Aug 01 2014
Biota Reports Top-Line Data From Its Phase 2 "IGLOO" Trial of Laninamivir Octanoate Aug 01 2014
Weekly 3-Year Low Highlights: CLUB, ARGS, ONTX, BOTA Jun 08 2014
BIOTA PHARMACEUTICALS, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities,... Jun 02 2014
Biota Pharma to cut to two-thirds of workforce Jun 02 2014
Biota Pharmaceuticals Inc Stock Downgraded (BOTA) May 29 2014
BIOTA PHARMACEUTICALS, INC. Financials May 20 2014
BIOTA PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report May 12 2014
34% Drop in Biota Pharmaceutical, Inc.'s Stock Price: Law Firm Investigates on Behalf of... May 12 2014
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In Biota... May 09 2014
Biota says U.S. agency terminates funding for flu drug May 08 2014
BIOTA PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 08 2014
Biota provides update on BARDA contract for laninamivir octanoate May 08 2014
Biota provides update on BARDA contract for laninamivir octanoate May 08 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK